Researchers have proposed that TP prostate biopsies be offered an option to all men.
It is associated with fewer positive surgical margins and reduced need for additional treatment.
Increasing health insurance coverage and access to usual source of care necessary to meet targets.
In a trial, more patients taking sildenfail citrate than placebo daily had functional erections at 24 months.
Complications other than urinary incontinence or erectile dysfunction occur frequently following treatment for PCa.
Blood loss is reduced and hospital stays are shorter compared with retropubic radical prostatectomy, but oncologic outcomes are similar.
Men who maintain good physical fitness have a lower risk of lung and colorectal cancer.
Prostate cancer patients who undergo RP by a different urologist are less likely to suffer surgical complications.
Compared with standard-dose radiotherapy, higher-dose radiotherapy was associated with better cancer control at 10 years.
High intake appears to be especially protective against lethal PCa, data show.
The term "personalized medicine" remains an overused promise to apply specific treatment plans.
High PSA and short PSA double time are associated with a greater likelihood of a positive bone scan.
D'Amico criteria incorrectly classified 37.5% of patients as having low-risk disease.
Transperineal technique should be offered as an option because it is associated with less sepsis than the transrectal approach.
Men with prostate cancer on active surveillance should be informed of the risk of complications.
A prostate cancer diagnosis was 54% more likely in men with metabolic syndrome.
In a Swedish study, three different radical prostatectomy approaches were associated with 9%-11% rates of hospital readmission.
Use of the drugs does not lower the risk of prostate cancer overall or of lower- or higher-risk disease.
Seventeen percent of Americans think that there is nothing people can do to change their risk.
Preoperative frailty increases the likelihood of postoperative complications among patients undergoing minimally invasive surgery.
Although several biomarkers show promise, PCA3 has garnered substantial attention following FDA approval and its role in the diagnosis of PCa will grow.
Patients diagnosed with the cancer in 2011 were 2.5 times more likely to be managed expectantly than those diagnosed in 2004.
Study findings show that expectant management (EM) of low-risk prostate cancer PCa is on the rise.
The risk of PCa death or distant metastases is 61% lower in men with blood group AB compared with those who have blood group O.
IMRT plus brachytherapy offers better PSA relapse-free and metastasis-free survival than high-dose IMRT alone.
Researchers found that PCa patients who walked at a faster pace were more likely to have healthier blood vessels.
And, combination radiotherapy, anti-androgen tx improves survival in locally advanced disease.
Researchers say their findings point to prostatic lycopene concentration as a promising biomarker of PCa.
The BRCA2 gene mutation is associated with a significantly increased likelihood of intermediate- or high-risk prostate cancer.
Researchers conducted a study in Iceland that found an association between prostate cancer risk and quality of sleep.